CytomX Therapeutics CTMX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.26M+1,447% | $663K-88.9% | $5.96M-68.0% | $18.66M-63.4% | $50.92M+33.7% | ||
| $19.24M-9.4% | $21.24M+38.8% | $15.3M+14.9% | $13.32M-29.4% | $18.87M+27.6% | ||
| $10.69M+45.3% | $7.36M+14.5% | $6.43M-2.9% | $6.62M-29.8% | $9.43M+67.6% | ||
| $29.93M+4.7% | $28.6M+31.6% | $21.73M+9.0% | $19.94M-29.5% | $28.3M+38.6% | ||
| $29.93M+4.7% | $28.6M+31.6% | $21.73M+9.0% | $19.94M-29.5% | $28.3M+38.6% | ||
| -$19.67M+29.6% | -$27.93M-77.1% | -$15.77M-1,126% | -$1.29M-106% | $22.62M+28.0% | ||
| -191.8%+4,021pp | -4,213%-3,949pp | -264.4%-258pp | -6.9%-51.3pp | 44.4%-2.0pp | ||
| $1.49M+0.6% | $1.48M-7.0% | $1.59M+35.1% | $1.18M+23.4% | $955K-25.3% | ||
| -$7K— | —— | $5K-70.6% | $17K+54.5% | $11K+158% | ||
| -$18.19M+31.2% | -$26.46M-86.7% | -$14.17M-15,473% | -$91K-100% | $23.59M+24.5% | ||
| $59K+9.3% | $54K-6.9% | $58K-7.9% | $63K+1.6% | $62K0.0% | ||
| -$18.25M+31.2% | -$26.51M-86.3% | -$14.23M-9,140% | -$154K-101% | $23.53M+24.6% | ||
| -177.9%+3,821pp | -3,998.5%-3,760pp | -238.6%-238pp | -0.8%-47.0pp | 46.2%-3.3pp | ||
| -$0.10+54.5% | -$0.22-144% | -$0.09— | -$0.00-100% | $0.27+17.4% | ||
| -$0.10+54.5% | -$0.22-144% | -$0.09— | -$0.00-100% | $0.27+17.4% | ||
| -$0.10+54.5% | -$0.22-144% | -$0.09— | -$0.00-100% | $0.27+17.4% | ||
| 177.3M+28.5% | 137.9M-16.4% | 165M+27.8% | 129.1M+48.1% | 87.2M+2.8% | ||
| 177.3M+28.5% | 137.9M-16.4% | 165M+27.8% | 129.1M+48.2% | 87.1M+3.2% | ||
| -$0.1+54.5% | -$0.22-144% | -$0.09— | -$0-100% | $0.27+17.4% | ||
| -$0.1+54.5% | -$0.22-144% | -$0.09— | -$0-100% | $0.27+17.4% | ||
| -$18.26M+31.1% | -$26.5M-87.2% | -$14.16M-11,698% | -$120K-101% | $23.5M+24.6% | ||
| —— | -$750.5K0.0% | -$750.5K0.0% | -$750.5K0.0% | -$750.5K— | ||
| -$9K-229% | $7K-90.1% | $71K+109% | $34K+221% | -$28K-115% | ||
| -$7K— | —— | $5K-70.6% | $17K+54.5% | $11K+158% | ||
| $10.26M+1,447% | $663K-88.9% | $5.96M-68.0% | $18.66M-63.4% | $50.92M+33.7% | ||
| -$19.67M+29.6% | -$27.93M-77.1% | -$15.77M-1,126% | -$1.29M-106% | $22.62M+28.0% | ||
| -$19.64M+29.6% | -$27.9M-77.3% | -$15.73M-1,160% | -$1.25M-106% | $22.66M+27.9% | ||
| -$19.64M+29.6% | -$27.9M-77.3% | -$15.73M-1,160% | -$1.25M-106% | $22.66M+27.9% | ||
| -191.4%+4,016pp | -4,207.4%-3,944pp | -263.8%-257pp | -6.7%-51.2pp | 44.5%-2.0pp | ||
| -$19.67M+29.6% | -$27.93M-77.1% | -$15.77M-1,126% | -$1.29M-106% | $22.62M+28.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $35.5M in revenue over the trailing twelve months, down 75.9% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $59.1M over the trailing twelve months, a -166.4% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.41.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
